New drug combo aims to wipe out lingering cancer cells in myeloma patients
NCT ID NCT06910124
Summary
This study is testing whether adding a new drug called linvoseltamab to standard lenalidomide maintenance therapy can help eliminate any remaining cancer cells in people with multiple myeloma. Researchers want to see if this combination can help patients achieve and maintain 'minimal residual disease negative' status, meaning no detectable cancer cells. The trial will enroll 32 adults who have already received initial treatment for newly diagnosed multiple myeloma and are currently on maintenance therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.